Is Diclofenac Safe for Heart Patients?

Diclofenac is not considered safe for people with established heart disease. European regulators formally contraindicated it in patients with serious cardiovascular conditions back in 2013, and a large Danish nationwide study found that people who started taking diclofenac had roughly 50 percent more cardiovascular events than those who did not use it at all.¹ What makes diclofenac’s story more complicated than a simple “avoid it” is that the drug remains widely available over the counter in many countries, the risks persist even at low doses, and the alternatives each carry their own trade-offs.

How Big Is the Cardiovascular Risk?

The most comprehensive data comes from a series of Danish nationwide cohort studies published in the BMJ, which tracked virtually the entire adult population of Denmark over multiple years. Compared with people who did not start any painkiller, diclofenac initiators had about a 50 percent higher rate of a combined cardiovascular endpoint that included heart attack, stroke, heart failure, irregular heart rhythm, and cardiac death. Broken down by event type, the increases were striking: roughly 90 percent higher for heart attack, 70 percent higher for heart failure, 60 percent higher for stroke, and 70 percent higher for cardiac death.¹

When the comparison shifted to other painkillers rather than no treatment, diclofenac still came out worse. Its event rate was about 20 percent higher than that of people starting paracetamol (acetaminophen) or ibuprofen, and about 30 percent higher than those starting naproxen.¹ Among patients who had already been hospitalized for serious coronary heart disease, the pattern held: diclofenac users had roughly 50 percent more serious cardiovascular events or deaths compared with naproxen users.²

One nuance worth noting: a review in Drug Safety pointed out that in the Danish data, the added risk from diclofenac actually shrank as a person’s baseline cardiovascular risk rose. In people already at very high risk, diclofenac did not appear worse than paracetamol or other NSAIDs. A separate multinational European study (the SOS project) found a slightly increased risk with diclofenac compared to non-use, but that risk was not dramatically different from other NSAIDs either.³ This does not mean diclofenac is safe for heart patients. It means that the entire NSAID class is risky in that population, and diclofenac tends to sit at or near the top of that risk.

Why Low Doses Do Not Solve the Problem

A common assumption, and one many people act on, is that taking a lower dose of diclofenac would sidestep the cardiovascular danger. The evidence says otherwise. A study that emulated a head-to-head trial of high-dose versus low-dose diclofenac found essentially identical cardiovascular risk between the two groups. The rate of major adverse cardiovascular events was about 55 percent higher for high-dose initiators and about 52 percent higher for low-dose initiators, each measured against a comparator group. When compared directly, there was no meaningful difference between the two doses.⁴

A second analysis from the same research group confirmed this. Looking at the composite of major cardiovascular and cerebrovascular events, the rate increase for high-dose diclofenac was about 73 percent and for low-dose about 68 percent, with no statistically meaningful gap between the two.⁵ The researchers explicitly warned against the assumption that low-dose diclofenac is “risk-neutral.” For heart patients, cutting the dose does not appear to offer cardiovascular protection.

Stroke Risk Specifically

The cardiovascular discussion often focuses on heart attacks, but stroke risk with diclofenac deserves separate attention because the data are fairly consistent across studies. A population-based case-control study found that diclofenac use was associated with about a 53 percent increase in ischemic stroke risk overall. At high doses, that rose to about 62 percent. Perhaps most alarming, long-term use beyond a year more than doubled the risk, and people who already had a high background cardiovascular risk saw an even larger increase.⁶

The multinational SOS project, which drew from several European databases, also found diclofenac associated with about a 26 percent increased risk of ischemic stroke compared with non-use. That placed diclofenac behind ketorolac (about 46 percent increase) but ahead of ibuprofen, nimesulide, and piroxicam.⁷ The message for anyone with cerebrovascular disease or stroke risk factors is the same as for coronary disease: diclofenac is one of the riskier choices.

How Diclofenac Stacks Up Against Other NSAIDs

The cardiovascular toxicity of NSAIDs is a class-wide problem, not something unique to diclofenac. But the degree of risk varies. Naproxen has long been considered the friendliest NSAID for the heart, and the data generally support that reputation. Ibuprofen sits in the middle. Diclofenac consistently lands near or at the top of the risk ladder among traditional NSAIDs.

What surprises many people is that diclofenac’s cardiovascular risk profile is comparable to the COX-2 selective inhibitors (coxibs) like celecoxib and etoricoxib, drugs that drew enormous attention for heart risk after rofecoxib (Vioxx) was pulled from the market. A Danish series of emulated trials found that diclofenac initiators had essentially the same rate of major adverse cardiovascular events as those starting celecoxib or etoricoxib.⁸ A separate study in patients with hypertension found no significant difference between celecoxib and diclofenac for cardiovascular events either.⁹

This coxib-like risk profile makes pharmacological sense. Although diclofenac is classified as a traditional (non-selective) NSAID, it actually inhibits the COX-2 enzyme quite potently. Its COX-2 selectivity is high enough that some researchers argue it should functionally be grouped with the coxibs rather than with ibuprofen or naproxen.³ That high COX-2 selectivity suppresses prostacyclin, a molecule that normally helps keep blood vessels dilated and discourages blood clotting, without fully suppressing thromboxane, which promotes clotting. The resulting imbalance tips the scales toward clot formation.

A Pharmacological Twist That Complicates the Picture

Despite its high COX-2 potency, diclofenac has a property that is unusual among NSAIDs: it blocks thromboxane receptors directly. Lab studies showed that diclofenac concentration-dependently inhibited smooth muscle contraction and human platelet aggregation triggered by thromboxane receptor activation, acting as a competitive antagonist at those receptors.¹⁰ In theory, this should partially offset the pro-clotting effect of COX-2 inhibition. Some researchers have speculated that without this property, diclofenac’s cardiovascular risk might be even higher than what we observe. Whether this thromboxane receptor blocking delivers any clinically meaningful protection in real patients remains uncertain, but it is a reminder that the pharmacology here is not as straightforward as the class-level warnings suggest.

Blood Pressure Effects

NSAIDs as a class can raise blood pressure by promoting sodium retention and reducing the effectiveness of antihypertensive medications. In the large MEDAL study, which compared diclofenac and etoricoxib in arthritis patients, a history of hypertension was the strongest predictor of blood pressure increases on either drug. Systolic blood pressure rose by roughly 3 mmHg more in patients with pre-existing hypertension. Age 65 and older was another strong predictor of exceeding safe blood pressure thresholds.¹¹

In that particular study, etoricoxib raised blood pressure more than diclofenac did, so diclofenac is not the worst offender in this specific domain. But for someone whose cardiovascular risk is already being driven by poorly controlled hypertension, even a modest additional bump in blood pressure from diclofenac can matter. The blood pressure rise also partly explains how NSAIDs contribute to heart failure: sustained elevation increases the workload on a heart that may already be struggling.

Does Diclofenac Interfere with Aspirin?

Many heart patients take low-dose aspirin daily to prevent clots. A natural concern is whether adding diclofenac might cancel out aspirin’s protective effect, since both drugs target the same family of enzymes. Ibuprofen is known to interfere with aspirin’s ability to block platelets if taken too close together, and some feared diclofenac would do the same.

A controlled study in healthy volunteers found that slow-release diclofenac taken alongside 80 mg of aspirin resulted in about 98 percent inhibition of platelet aggregation, essentially no interference.¹² A separate study observed a slight reduction in aspirin’s antiplatelet effect during the first couple of days of co-administration, but this disappeared by about day four.¹³ So unlike ibuprofen, diclofenac does not appear to significantly blunt aspirin’s antiplatelet action. That is a small silver lining, but it does not change the bigger picture: the cardiovascular risk from diclofenac comes from other mechanisms (prostacyclin suppression, blood pressure elevation, fluid retention), not from interfering with aspirin.

Topical Diclofenac as a Possible Workaround

If you need diclofenac for localized joint or muscle pain, the topical gel or patch version might be a safer bet for your heart. The reason is simple: far less drug reaches the bloodstream. A pharmacokinetic study in healthy volunteers found that systemic exposure from topical diclofenac gel was 5 to 17 times lower than from oral diclofenac. The topical form did not inhibit platelet aggregation and had weaker effects on the enzyme pathways involved in cardiovascular risk.¹⁴

A Taiwanese study of patients with rheumatoid arthritis put numbers on the difference in outcomes. Topical NSAID users had about 36 to 46 percent lower risk of cardiovascular events compared with oral NSAID users, depending on the statistical model used.¹⁵ A review focused specifically on pain management in heart failure patients noted that topical pain medications are preferred because of their efficacy, tolerability, and more favorable side-effect profile.¹⁶

Topical diclofenac is not zero-risk. Some drug still gets absorbed, and if you are applying it over large areas of your body multiple times a day, the systemic exposure climbs. But for a single sore knee or an aching shoulder, it is a fundamentally different proposition than swallowing a pill.

Regulatory Actions and What They Mean in Practice

In 2013, the European Medicines Agency recommended new contraindications for diclofenac across Europe, specifically advising against its use in patients with established cardiovascular disease, including those with a history of heart attack, stroke, or heart failure.¹⁷ The U.S. FDA, while not singling out diclofenac by name in the same way, strengthened its warnings for all NSAIDs starting in 2005 and again in 2015, requiring labels to state that cardiovascular risk can begin within the first weeks of use.

Despite these regulatory moves, diclofenac remains available without a prescription in many parts of the world. A study surveying public awareness in Saudi Arabia found that knowledge about diclofenac’s side effects was generally poor, leaving people who self-medicate exposed to risks they do not understand.¹⁸ This gap between regulatory warnings and street-level awareness is one of the more troubling aspects of the diclofenac safety story. The people who most need to know about the risk are often the ones buying the drug without consulting a doctor.

Genetic Variability in How Your Body Handles Diclofenac

Not everyone processes diclofenac the same way. The drug is mainly broken down in the liver by the enzyme CYP2C9, and genetic variations in the gene encoding that enzyme are common. Some people carry variants that slow the enzyme down, meaning diclofenac sticks around longer and reaches higher concentrations in the blood. The Clinical Pharmacogenetics Implementation Consortium (CPIC) has published guidelines noting that CYP2C9 polymorphisms influence the metabolism and clearance of several NSAIDs, including diclofenac, potentially affecting safety.¹⁹

If you are a “poor metabolizer” of CYP2C9, a standard dose of diclofenac may produce higher blood levels than expected, amplifying both its therapeutic effects and its risks. Pharmacogenetic testing is not routine before prescribing NSAIDs, but if you already know your CYP2C9 status from other testing (it also affects drugs like warfarin), it is worth flagging to your doctor. People of certain ancestral backgrounds carry these slower-metabolizing variants more frequently, though the variants appear across all populations.

What Heart Patients Should Actually Use for Pain

The pain management landscape for people with cardiovascular disease is frustratingly narrow. Reviews of pharmacological management for heart failure patients consistently recommend acetaminophen (paracetamol) as the first-line oral analgesic, since it does not carry the same cardiovascular or renal risks as NSAIDs.¹⁶ It is weaker for inflammatory pain, though, which is where the dilemma begins. Naproxen is often considered the least cardiovascularly harmful NSAID when an anti-inflammatory is truly needed, though it is not risk-free either. Topical NSAIDs, as discussed, offer a useful middle ground for localized pain. Non-drug approaches like physical therapy, heat, ice, and targeted exercise programs do not carry cardiovascular risk at all and are underused.

For people with chronic inflammatory conditions like rheumatoid arthritis who genuinely need ongoing NSAID therapy, the conversation with a cardiologist becomes essential. Sometimes the trade-off between controlling a debilitating inflammatory disease and accepting a degree of cardiovascular risk is the best option available. But that trade-off should be made consciously, with the patient understanding the magnitude of risk, not discovered after a cardiac event.